Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Michetti

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Digestive Diseases (Basel, Switzerland)|September 15, 2015
Postsurgical Prophylaxis in Crohn's Disease: Which Patients, Which Agents?Pierre Michetti
Digestive Diseases (Basel, Switzerland)|September 30, 2009
Fistula treatment: the unresolved challengePierre Michetti
Revue Medicale Suisse|January 25, 2024
Pierre Michetti
Nature Clinical Practice. Gastroenterology & Hepatology|October 15, 2005
What is the impact of polypharmacy in patients with Crohn's disease?Pierre Michetti
Revue Medicale Suisse|March 14, 2008
[Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease]Pierre Michetti
Revue Medicale Suisse|January 30, 2020
Pierre Michetti
Revue Medicale Suisse|February 24, 2006
[A mix for progress]Pierre Michetti
Lancet (London, England)|December 7, 2017
Efficacy of infliximab biosimilars in patients with Crohn's diseasePierre Michetti
Revue Medicale Suisse|March 18, 2005
[2005, a year of consolidation]Pierre Michetti
Journal of Crohn'S & Colitis|November 20, 2015
A Look Beyond the Biosimilarity of the MoleculesPierre Michetti
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Digestive Diseases (Basel, Switzerland)|September 15, 2015
Postsurgical Prophylaxis in Crohn's Disease: Which Patients, Which Agents?Pierre Michetti
Digestive Diseases (Basel, Switzerland)|September 30, 2009
Fistula treatment: the unresolved challengePierre Michetti
Revue Medicale Suisse|January 25, 2024
Pierre Michetti
Nature Clinical Practice. Gastroenterology & Hepatology|October 15, 2005
What is the impact of polypharmacy in patients with Crohn's disease?Pierre Michetti
Revue Medicale Suisse|March 14, 2008
[Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease]Pierre Michetti
Revue Medicale Suisse|January 30, 2020
Pierre Michetti
Revue Medicale Suisse|February 24, 2006
[A mix for progress]Pierre Michetti
Lancet (London, England)|December 7, 2017
Efficacy of infliximab biosimilars in patients with Crohn's diseasePierre Michetti
Revue Medicale Suisse|March 18, 2005
[2005, a year of consolidation]Pierre Michetti
Journal of Crohn'S & Colitis|November 20, 2015
A Look Beyond the Biosimilarity of the MoleculesPierre Michetti
Pageof 15